EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics

Bo Yang, Juan Liu iD, Yang Li, Xiaoxuan Liu

Cancer Innovation · 2025-12 · 4 (6)

DOI: 10.1002/cai2.70041 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Innovation, online erschienen am 08.12.2025. Verfasst von Bo Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Screening and Evaluation Chia Tai Tianqing Pharmaceutical Group Co., Ltd Nanjing Jiangsu China. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 191 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The groundbreaking success of messenger RNA (mRNA) vaccines during the COVID‐19 pandemic has significantly accelerated their application in oncology. This review comprehensively synthesizes the recent advancements in mRNA cancer vaccine development, emphasizing three critical domains: mechanistic innovations, clinical translation, and ongoing challenges. Technologically, advancements in nucleotide modification, lipid nanoparticle (LNP) delivery systems, and AI‐driven neoantigen selection have significantly improved vaccine stability, immunogenicity, and personalization. Clinically, more than 150 trials have demonstrated the synergistic efficacy of mRNA vaccines (e.g., mRNA‐4157/V940, BNT122) in combination with immune checkpoint inhibitors (ICIs), particularly in melanoma, with Phase III trials currently underway. Individualized neoantigen vaccines targeting patient‐specific mutations have shown unprecedented response rates (> 50% in certain cohorts), while shared‐antigen vaccines are progressing for high‐incidence cancers. However, several critical challenges remain: (1) overcoming immunosuppressive tumor microenvironments (TME), (2) addressing systemic toxicities and LNP‐related limitations, (3) scaling up cost‐effective personalized manufacturing, and (4) optimizing targeted delivery. Future research directions encompass self‐amplifying mRNA constructs, novel biomaterial vectors, neoadjuvant applications, and multi‐omics integration for next‐generation vaccine development. With rapid industrialization and evolving regulatory frameworks, mRNA vaccines are well‐positioned to revolutionize precision cancer immunotherapy despite persistent translational barriers.

Schlagwörter

Stichwörter der Autor:innen

cancer vaccinesimmunotherapymRNA

Autor:innen und Institutionen

  • Department of Drug Screening and Evaluation Chia Tai Tianqing Pharmaceutical Group Co., Ltd Nanjing Jiangsu China.
  • School of International Pharmaceutical Business, China Pharmaceutical University Nanjing Jiangsu China.
  • Hepato-Pancreato-Biliary Center, Beijing Tsinghua Changgung Hospital, Key Laboratory of Digital Intelligence Hepatology (Ministry of Education), School of Clinical Medicine, Tsinghua Medicine, Tsinghua University Beijin…
  • State Key Laboratory of Natural Medicines, Joint International Research Laboratory of Target Discovery and New Drug Innovation (Ministry of Education), Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Ce…

ORCID-Profile: Juan Liu

Zitieren

APA

Yang, B., Liu, J., Li, Y., & Liu, X. (2025). mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics. Cancer Innovation, 4(6). https://doi.org/10.1002/cai2.70041

Vancouver

Yang B, Liu J, Li Y, Liu X. mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics. Cancer Innovation. 2025;4(6). doi:10.1002/cai2.70041

BibTeX
@article{Yang2025,
  author = {Yang, Bo and Liu, Juan and Li, Yang and Liu, Xiaoxuan},
  title = {mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics},
  journal = {Cancer Innovation},
  year = {2025},
  volume = {4},
  number = {6},
  doi = {10.1002/cai2.70041}
}
Kostenlos starten →